4/18/2024

Adenosine Injection

Products Affected - Description

- Adenosine intravenous injection, Eugia US, 3 mg/mL, 20 mL vial, 1 count, NDC 55150-0192-01
- Adenosine intravenous injection, Fresenius Kabi, 3 mg/mL, 20 mL vial, 1 count, NDC 63323-0651-20

Reason for the Shortage

- Akorn ceased operations in February 2023.
- Pfizer discontinued adenosine in late-2022.
- Eugia did not provide a reason for the shortage.
- Fresenius Kabi did not provide a reason for the shortage.
- Sagent has adenosine injection available.
- Teva is not currently marketing adenosine injection.
- Viatris has adenosine injection available.

Available Products

- Adenosine intravenous injection, Eugia US, 3 mg/mL, 30 mL vial, 1 count, NDC 55150-0193-01
- Adenosine intravenous injection, Fresenius Kabi, 3 mg/mL, 30 mL vial, 1 count, NDC 63323-0651-30
- Adenosine intravenous injection, Mylan (Viatris), 3 mg/mL, 20 mL vial, 1 count, NDC 67457-0856-20
- Adenosine intravenous injection, Mylan (Viatris), 3 mg/mL, 30 mL vial, 1 count, NDC 67457-0857-30
- Adenosine intravenous injection, Fresenius Kabi, 3 mg/mL, 2 mL syringe, 10 count, NDC 63323-0651-89
- Adenosine intravenous injection, Fresenius Kabi, 3 mg/mL, 2 mL vial, 10 count, NDC 63323-0651-02
- Adenosine intravenous injection, Fresenius Kabi, 3 mg/mL, 4 mL syringe, 10 count, NDC 63323-0651-90
- Adenosine intravenous injection, Fresenius Kabi, 3 mg/mL, 4 mL vial, 10 count, NDC 63323-0651-04
- Adenosine intravenous injection, Mylan (Viatris), 3 mg/mL, 2 mL vial, 10 count, NDC 67457-0855-02
- Adenosine intravenous injection, Mylan (Viatris), 3 mg/mL, 4 mL vial, 10 count, NDC 67457-0854-04
- Adenosine intravenous injection, Sagent, 3 mg/mL, 2 mL prefilled syringe, 10 count, NDC 25021-0301-67
- Adenosine intravenous injection, Sagent, 3 mg/mL, 2 mL vial, 10 count, NDC 25021-0318-02
- Adenosine intravenous injection, Sagent, 3 mg/mL, 4 mL prefilled syringe, 10 count, NDC 25021-0301-68
- Adenosine intravenous injection, Sagent, 3 mg/mL, 4 mL vial, 10 count, NDC 25021-0318-04

Estimated Resupply Dates

- Eugia has adenosine 3 mg/mL 20 mL vials on back order and the company estimates a release date of May to June 2024. Short-dated product is available.
- Fresenius Kabi has adenosine short-dated 3 mg/mL 20 mL vials available with an expiration date of < 8 months.

Updated

Updated April 18, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created April 3, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.